The article discusses the significant impact of testosterone levels on prostate cancer outcomes, highlighting that low testosterone at diagnosis (< 8.0 nmol/L) is associated with a 67% increased risk of mortality compared to normal levels (> …
Zytiga, known generically as abiraterone, is a hormone therapy drug used to treat advanced prostate cancer, particularly in patients whose cancer has progressed despite previous treatments. It works by inhibiting testosterone production, crucial for …
Nubeqa, or darolutamide, is a promising treatment for prostate cancer, particularly for nonmetastatic castration-resistant and hormone-sensitive metastatic forms. As an androgen receptor inhibitor, it blocks testosterone from fueling cancer cell …
Xtandi, or enzalutamide, is a revolutionary treatment for advanced prostate cancer, particularly effective in nonmetastatic castration-sensitive cases as per recent FDA approvals. By inhibiting the androgen receptor signaling pathway, Xtandi reduces …
The article discusses various types of hormone therapy for prostate cancer, which aim to lower testosterone levels or block its effects on cancer cells. Key therapies include LHRH agonists (e.g., goserelin, leuprolide), anti-androgens (e.g., …
Provenge, or sipuleucel-T, is the first FDA-approved therapeutic cancer vaccine for advanced prostate cancer, offering a novel approach to enhance the immune response in patients with this disease. Unlike preventive vaccines, Provenge is designed for …
Trelstar, a brand-name drug containing triptorelin, is a crucial hormone therapy for advanced prostate cancer, approved by the FDA for palliative treatment. As a gonadotropin-releasing hormone (GnRH) agonist, it suppresses testosterone production, …
Eligard (leuprolide acetate) is an LHRH agonist that effectively suppresses testosterone production, primarily used for treating advanced and hormone-sensitive prostate cancer. Administered via subcutaneous injection, it works by inhibiting the …
Casodex is a prescription medication used to treat stage D2 metastatic prostate cancer by acting as an androgen receptor inhibitor, blocking testosterone’s effects on cancer cells. It is commonly administered with a luteinizing …
Zytiga, or abiraterone acetate, is an oral medication used primarily for metastatic castration-resistant prostate cancer (mCRPC). It works by inhibiting the CYP17 enzyme, reducing androgen production and thus lowering testosterone levels, which can …
